X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.prnewswire.com/news-releases/post-hoc-analysis-showed-cimzia-certolizumab-pegol-resulted-in-meaningful-efficacy-for-ra-patients-with-high-levels-of-rheumatoid-factor-rf-301985174.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125160
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125160
https://www.globenewswire.com/news-release/2022/02/07/2380345/0/en/Biogen-and-Xbrane-Announce-Commercialization-and-License-Agreement-for-Proposed-Biosimilar-Referencing-CIMZIA-Certolizumab-pegol-with-the-Potential-to-Treat-Rheumatoid-Arthritis.html
https://www.ucb.com/stories-media/Press-Releases/article/UCB-Presents-Nine-Abstracts-at-EADV-2020-Showcasing-Ongoing-Commitment-to-Dermatology
https://www.clinicaltrialsarena.com/projects/cimzia-certolizumab-pegol-treatment-moderate-severe-plaque-psoriasis/
http://www.pharmafile.com/news/555505/ema-expands-label-ucbs-cimzia-axial-spondyloarthritis
https://www.ucb.com/stories-media/Press-Releases/article/CIMZIA-is-the-First-and-Only-Biologic-Approved-in-Europe-with-the-Option-for-a-Reduced-Maintenance-Dose-for-Patients-Across-the-Full-Axial-Spondyloarthritis-Spectrum
https://www.prnewswire.com/news-releases/ucb-and-ferring-pharmaceuticals-announce-co-promotion-of-cimzia-certolizumab-pegol-for-the-treatment-of-adults-with-moderate-to-severe-crohns-disease-301089326.html
https://www.selectscience.net/product-news/bio-rad-launches-anti-certolizumab-pegol-antibodies/?&artID=51430
https://www.prnewswire.com/news-releases/ucbs-cimzia-is-making-inroads-in-the-treatment-of-axial-disease-with-significant-uptake-in-non-radiographic-axial-spondyloarthritis-and-a-positive-treatment-halo-in-ankylosing-spondylitis-301048947.html
https://www.thepharmaletter.com/article/ucb-continues-global-development-of-cimzia
http://www.pharmatimes.com/news/nice_final_guidance_published_for_cimzia_1284942
http://www.pharmatimes.com/news/fda_label_expansion_for_ucbs_cimzia_1282911
https://www.prnewswire.com/news-releases/cimzia-certolizumab-pegol-is-now-the-first-and-only-us-fda-approved-treatment-for--non-radiographic-axial-spondyloarthritis-300820746.html
http://www.pharmatimes.com/news/nice_nod_for_almiralls_ilumetri,_ucbs_cimzia_1280960
http://www.pharmafile.com/news/518764/ucb-brings-promising-plaque-psoriasis-data-eadv-2018
Market Place
Share 
